Foresite Capital Management Iv, LLC Uni Qure N.V. Transaction History

Foresite Capital Management Iv, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$45.06 - $67.74 $859,834 - $1.29 Million	-19,082 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$40.01 - $73.97 $763,470 - $1.41 Million	19,082 New	19,082 $905,000
Q4 2018 Feb 13, 2019	SELL	$22.8 - $33.93 $242,820 - $361,354	-10,650 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$21.96 - $39.94 $12.1 Million - $21.9 Million	-549,423 Reduced 98.1%	10,650 $403,000
Q1 2018 May 15, 2018	SELL	$17.1 - $26.61 $1.29 Million - $2 Million	-75,161 Reduced 11.83%	560,073 $13.2 Million
Q4 2017 Feb 13, 2018	BUY	$9.47 - $19.59 $6.02 Million - $12.4 Million	635,234	635,234 $12.4 Million

154

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $825M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iv, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Iv, LLC with notifications on news.